Sanofi has been granted marketing authorization by the European Commission for its dengue vaccine, Dengvaxia, following the earlier recommendation of approval by the EMA's CHMP
In a Dec. 19, 2018 press release, Sanofi revealed that it has been granted marketing authorization by the European Commission for its dengue vaccine, Dengvaxia, following the earlier recommendation of approval by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).
This marketing authorization will mean that European patients aged 9–45 years with prior dengue infection, who are living in endemic areas, will be able to receive the preventative treatment, Dengvaxia.
“In some of the European overseas territories where dengue recurs regularly, people who have had a dengue infection previously are at risk of being infected with the virus again,” explained Su-Peing Ng, global medical head at Sanofi Pasteur, the vaccine unit of Sanofi. “As the second infection with dengue tends to be more severe than the first, it is important to be able to offer these people a vaccine that could help protect them against subsequent dengue infections.”
The dengue vaccine is currently approved for use in several endemic countries in Latin America and Asia and is under priority review by FDA.
Source: Sanofi
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.